Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Taus García, Álvaro
• dc.contributor.author Remon, Jordi
• dc.contributor.author Esteller, Laura
• dc.contributor.author Taus García, Álvaro
• dc.date.accessioned 2019-11-21T07:36:20Z
• dc.date.available 2019-11-21T07:36:20Z
• dc.date.issued 2019
• dc.description.abstract Immune checkpoint inhibitors (ICI) as monotherapy in selected patients as well as in combination with chemotherapy have become the standard of care in the first-line treatment strategy of advanced non-small cell lung cancer (NSCLC) patients. Combination treatment with ICI, such as nivolumab and ipilimumab or durvaluamb and ipilimumab, has also been proposed as potential strategies in this setting in selected advanced NSCLC patients. Characterizing predictive markers of long-term clinical benefit with ICI is a critical objective. Tumor mutational burden has been proposed as a potential predictive biomarker. In this review, we discuss the efficacy of nivolumab and ipilimumab in advanced NSCLC patients as well as the clinical utility of tumor mutational burden in the efficacy of this combination. Ongoing clinical trials with nivolumab and ipilimumab, and the efficacy of this combination in subgroups of NSCLC patients, such as elderly patients and patients with brain metastases, are also discussed.
• dc.format.mimetype application/pdf
• dc.identifier.citation Remon J, Esteller L, Taus Á. Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date. Cancer Manag Res. 2019 May 29;11:4893-4904. DOI 10.2147/CMAR.S164935
• dc.identifier.doi http://dx.doi.org/10.2147/CMAR.S164935
• dc.identifier.issn 1179-1322
• dc.identifier.uri http://hdl.handle.net/10230/42915
• dc.language.iso eng
• dc.publisher Dove Medical Press
• dc.rights Copyright © 2019 Remon et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc/3.0/
• dc.subject.keyword CheckMate trial
• dc.subject.keyword Ipilimumab
• dc.subject.keyword Nivolumab
• dc.subject.keyword Non-small cell lung cancer
• dc.subject.keyword Tumor mutational burden
• dc.title Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion